Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T18:53:05.671Z.
Calculation as of: 2026-10-06T18:53:05.671Z.
Quote observation: 2026-10-06T18:50:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 08fea6a2878daf509c4a2714b7418dcfec0265989d531cb4479ebc608e1bd708
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Sagimet Biosciences Inc.
Market Cap
$285.42M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.38M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.46M
Operating Cash Flow Yield
N/A
TTM Avg
2.67%
3Y Avg
2.67%
5Y Avg
2.67%
Market Cap
$286.69M
Operating Cash Flow Yield
N/A
TTM Avg
1.81%
3Y Avg
1.81%
5Y Avg
1.81%
Market Cap
$283.58M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$287.63M
Operating Cash Flow Yield
N/A
TTM Avg
41.23%
3Y Avg
41.23%
5Y Avg
41.23%
Market Cap
$281.92M
Operating Cash Flow Yield
N/A
TTM Avg
1.84%
3Y Avg
1.84%
5Y Avg
1.84%
Market Cap
$291.71M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.54M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. (SGMT) | $285.42M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $285.38M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.46M | N/A | 2.67% | 2.67% | 2.67% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.69M | N/A | 1.81% | 1.81% | 1.81% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.58M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | N/A | 41.23% | 41.23% | 41.23% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A | 1.84% | 1.84% | 1.84% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.71M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $271.54M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.34M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
